Advertisement

Haemonetics Corporation HAE

Set alert

Price alert · HAE

All alert types
120.14 USD +0.49 +0.41%

At close · Nov 2

120.14 0.00 0.00%

After hours · Nov 2, 4:05 PM ET

Bid
120.14 × 300
Ask
120.73 × 700
119.08 Day range 121.43
49.24 52-week range 123.77
YTD
+49.89%
1 year
+140.23%
Open
120.36
Prev close
119.65
Mkt cap
5.47B
Vol
678.59K
Avg vol
725.65K
EPS
2.07
P/E
58.04
Div yield
0.00%
More statistics
Low
119.08
High
121.43
Forward P/E
20.82
Beta
0.59
Short ratio
4.81
Inst. own
112.08%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
109.98
200-d avg
78.64
1y target
124.50

15m chart

Chart tools
Interval

Built from the cached five-day intraday bars.

Signals (36)
NameTimeAgo
SMA: BullishOct 30, 3:55 PM3 days ago
MACD: Buy SignalOct 30, 3:55 PM3 days ago
SMA: BullishOct 30, 3:25 PM3 days ago
MACD: Sell SignalOct 30, 12:25 PM3 days ago
SMA: BearishOct 30, 12:10 PM3 days ago
SMA: BearishOct 30, 12:10 PM3 days ago
MACD: Buy SignalOct 30, 11:25 AM3 days ago
SMA: BullishOct 30, 11:10 AM3 days ago
SMA: BullishOct 30, 11:10 AM3 days ago
SMA: BearishOct 30, 10:55 AM3 days ago
SMA: BearishOct 30, 10:55 AM3 days ago
SMA: BullishOct 30, 10:40 AM3 days ago
SMA: BullishOct 30, 10:40 AM3 days ago
SMA: BearishOct 30, 10:10 AM3 days ago
SMA: BearishOct 30, 9:55 AM3 days ago
MACD: Sell SignalOct 30, 9:55 AM3 days ago
MACD: Buy SignalOct 30, 9:40 AM3 days ago
SMA: BullishOct 29, 3:40 PM4 days ago
SMA: BearishOct 29, 3:25 PM4 days ago
SMA: BullishOct 29, 3:10 PM4 days ago
SMA: BearishOct 29, 2:55 PM4 days ago
SMA: BullishOct 29, 2:25 PM4 days ago
MACD: Sell SignalOct 29, 1:40 PM4 days ago
SMA: BearishOct 29, 12:40 PM4 days ago
RSI: OverboughtOct 29, 11:25 AM4 days ago
SMA: BullishOct 29, 9:55 AM4 days ago
SMA: BullishOct 29, 9:40 AM4 days ago
MACD: Buy SignalOct 29, 9:40 AM4 days ago
MACD: Sell SignalOct 28, 3:55 PM5 days ago
SMA: BearishOct 28, 2:40 PM5 days ago
MACD: Buy SignalOct 28, 1:25 PM5 days ago
SMA: BullishOct 28, 1:10 PM5 days ago
SMA: BearishOct 27, 3:40 PM6 days ago
SMA: BullishOct 27, 2:10 PM6 days ago
RSI: OverboughtOct 27, 2:10 PM6 days ago
SMA: BearishOct 27, 1:10 PM6 days ago

Key statistics

Market cap
5.47B
Enterprise value
6.39B
Trailing P/E
58.10
Forward P/E
20.82
PEG ratio
1.90
Price / sales
4.05
Price / book
6.53
EPS (TTM)
2.07
Beta
0.59
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
7.12%
Revenue (TTM)
1.35B
Revenue growth
5.60%
Free cash flow
312.84M
Total cash
224.52M
Total debt
1.17B
Return on equity
11.20%
Shares outstanding
45.50M
Short % of float
8.82%
50-day average
109.98
200-day average
78.64

Analyst view

Consensus: buy

Buy
Price target (mean) 124.50 +3.6% upside
Target (low)
86.00
Target (mean)
124.50
Target (high)
142.00
Ratings (0m) 11 9 buy · 2 hold · 0 sell
  • Strong buy4
  • Buy5
  • Hold2
  • Sell0
  • Strong sell0

Next earnings

Nov 5, 2026

Expected Nov 5, 2026. Consensus EPS estimate 1.29.

Earnings history

Financials — quick view

All financials
HAE Revenue — quarterly 339.38M
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026
HAE Net income — quarterly 33.01M
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026
HAE EPS — quarterly 0.73
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026

Earnings

HAE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 27, 20261.29———
Aug 6, 2026Jun 27, 20261.081.14+0.06+5.56%
May 7, 2026Mar 28, 20261.281.29+0.01+0.78%
Feb 5, 2026Dec 27, 20251.271.31+0.04+3.15%
Nov 6, 2025Sep 27, 20251.121.27+0.15+13.39%
Aug 7, 2025Jun 28, 20251.011.10+0.09+8.91%

Upgrades / downgrades

HAE analyst upgrades and downgrades
DateFirmActionFromTo
Oct 9, 2026Barrington ResearchmainOutperformOutperform
Oct 9, 2026MizuhomainOutperformOutperform
Oct 8, 2026BTIGmainBuyBuy
Sep 17, 2026CitigroupupNeutralBuy
Sep 3, 2026Raymond JamesmainOutperformOutperform
Aug 21, 2026BairdmainOutperformOutperform

About Haemonetics Corporation

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on HAE — it syncs with the Stock Master app.

Insider holders

HAE insider holders
InsiderRelationLatest transactionDateShares held
ABERNATHY ROBERT EDirectorStock Award(Grant)Jul 23, 202627,519
BASIL MICHELLE LGeneral CounselStock Award(Grant)May 14, 202668,829
DARECCA JAMESChief Financial OfficerStock Award(Grant)May 14, 202654,444
DOCKENDORFF CHARLES JDirectorStock Award(Grant)Jul 23, 202525,041
GALVIN ROYOfficerStock Award(Grant)May 14, 202639,882
KROLL MARK WDirectorStock Award(Grant)Jul 23, 202627,295

Institution ownership

HAE institution ownership
Holder% heldSharesValueReported
Blackrock Inc.12.99%5,909,258710.65MJun 29, 2026
Neuberger Berman Group, LLC9.19%4,179,443502.62MJun 29, 2026
Vanguard Portfolio Management LLC5.60%2,546,394306.23MJun 29, 2026
AQR Capital Management, LLC4.98%2,266,489272.57MJun 29, 2026
Vanguard Capital Management LLC4.53%2,059,578247.68MJun 29, 2026
Ariel Investments, LLC4.53%2,060,966247.85MJun 29, 2026

Fund ownership

HAE fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%1,621,301194.98MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%1,441,654173.37MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.62%1,194,166143.61MSep 29, 2026
NEUBERGER BERMAN EQUITY FUNDS-Neuberger Genesis Fund2.59%1,179,168141.81MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%1,041,356125.23MJun 29, 2026
Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com1.35%614,82473.94MJun 29, 2026
Advertisement